1 / 16

Sivextro ™ (tedizolid phosphate)

Sivextro ™ (tedizolid phosphate). Manufacturer: Cubist Pharmaceuticals FDA Approval Date: June 20, 2014. Sivextro ™ - tedizolid phosphate Clinical Application. Indications: Acute bacterial skin and skin structure infections Susceptible Gram-positive organisms Place in therapy:

allen-wheeler
Download Presentation

Sivextro ™ (tedizolid phosphate)

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Sivextro™(tedizolid phosphate) Manufacturer: Cubist Pharmaceuticals FDA Approval Date: June 20, 2014

  2. Sivextro™ - tedizolid phosphateClinical Application • Indications: • Acute bacterial skin and skin structure infections • Susceptible Gram-positive organisms • Place in therapy: • First line against gram positives? • Think good antimicrobial stewardship

  3. Sivextro™ - tedizolid phosphateClinical Application • Contraindications: • None • Warnings and Precautions: • Neutropenia (<1000 cells/mm3) • Bacterial or Fungal Super-infections

  4. Sivextro™ - tedizolid phosphateClinical Application • Pregnancy: • Category C • Adverse event noted in animal studies • Lactation: • Not known if it enters breast milk

  5. Sivextro™ - tedizolid phosphateDrug Facts • Pharmacology: • Prodrug (tedizolid phosphate  tedizolid) • Binds to the 50S bacterial ribosomal subunit • Bacteriostatic against • Enterococci • Staphylococci • Streptococci

  6. Sivextro™ - tedizolid phosphateDrug Facts

  7. Sivextro™ - tedizolid phosphateDrug Interactions • Drug Interactions – Object Drugs: • No known drug interactions • Drug interactions – Precipitant Drugs: • No known drug interactions

  8. Sivextro™ - tedizolid phosphateAdverse Effects

  9. Sivextro™ - tedizolid phosphateMonitoring Parameters • Efficacy Monitoring: • Signs of clinical improvement • Toxicity Monitoring: • Reduction in circulation RBCs, WBCs, and platelets

  10. Sivextro™ - tedizolid phosphatePrescription Information • Dosing: • 200 mg Oral or Intravenous • Infusion time 1 hour • Daily for six days • IV to oral – no dose adjustment

  11. Sivextro™ - tedizolid phosphatePrescription Information • Cost: Lexi-Comp via UpToDate; Accessed 10/16/2014

  12. Sivextro™ - tedizolid phosphateLiterature Review • Study Design (ESTABLISH-1) • Phase 3, randomized, double blind, double dummy, non-inferiority trial • 81 study centers from North America, Latin American and Europe • Interventions • Tedizolid 200 mg daily for 6 days • Linezolid 600 mg twice daily for 10 days Prokocimer et al., JAMA. 2013;309(6):559-569

  13. Sivextro™ - tedizolid phosphateLiterature Review • Endpoints • Primary • Early clinical response (48-72hr) • Temp ≤ 37.6°C • Cessation of primary lesion spread • Classified as responders, non-responders, and indeterminate Prokocimer et al., JAMA. 2013;309(6):559-569

  14. Sivextro™ - tedizolid phosphateLiterature Review Prokocimer et al., JAMA. 2013;309(6):559-569

  15. Sivextro™ - tedizolid phosphateSummary • Sivextro is a new oxazolidinone for acute bacterial skin and skin structure infections for gram positive organisms. • IV or oral 200 mg once daily dosing. • It has a simple metabolism and does not interfere with other medications • Sivextro should be used as a second line medication for ABSSSI. More uses could become available.

  16. Sivextro™ - tedizolid phosphateReferences • http://sivextro.com/. 10/14. • Sivextro package insert. Cubist. October 2014. • Prokocimer et al., Tedizolid Phosphate vs Linezolid for Treatment of Acute Bacterial Skin and Skin Structure Infections. JAMA. 2013;309(6):559-569

More Related